New drug fizzles at raising HDL
New drug fizzles at raising HDL
Tried-and-true strategies are still excellent ways to boost good cholesterol.
When pharmaceutical giant Pfizer pulled the plug on torcetrapib, its experimental HDL-raising drug, media reports made it sound like we were losing our last, best ally in the battle against heart disease. The decision was unquestionably a huge setback for Pfizer, which had sunk $800 million into developing torcetrapib. And it was a big bump in the road for researchers hoping that high-density lipoprotein (HDL, the so-called good cholesterol) would be the next big thing in cholesterol-targeted drug therapy. But it shouldn't be taken as a sign that raising HDL is a bad or dangerous strategy for preventing heart disease and stroke — just that torcetrapib isn't the way to do it.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
